Launch week: the AltIndex Developer API is live. 25% off all plans with code LAUNCHWEEKSee plans
46 / 100
AltIndex AI Score
Hold
AI Score · 12-mo trend
−5 pts over 3 months50% of HAE’s tracked signals bullish
FundamentalsNeutral
TechnicalsNeutral
Alternative dataNeutral
SentimentBullish
Price$102.69
Year Range$52.24 – $108.8
Market Cap$4.67B
PE Ratio49.61
IndustryMedical Devices

What Is Haemonetics Corporation’s AI Stock Analysis?

Haemonetics Corporation’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Haemonetics Corporation’s momentum in near-real time.

Haemonetics Corporation (HAE) has an AltIndex AI Score of 46/100, currently a Hold signal. The AI Score distills Haemonetics Corporation's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.

Haemonetics Corporation’s Full AI Analysis

Haemonetics Corporation is a global healthcare company dedicated to providing innovative blood management solutions. The company operates through several business segments, including Plasma, Blood Center, and Hospital. Haemonetics is renowned for its sophisticated blood technology systems aimed at optimizing blood collection, processing, and delivery, ultimately promoting improved patient care.

Fundamental Analysis

Revenue for the last quarter was $339 million. This represents a decrease of 2.01% compared to the quarter before it, indicating some potential short-term volatility. However, compared to the same quarter last year, there is an increase of 5.60%, suggesting positive year-over-year growth. This indicates that Haemonetics Corporation has been able to grow its revenue consistently over the past year, which is a positive sign for investors who are considering long-term growth.

Premium

Keep reading AltIndex’s full AI analysis of Haemonetics Corporation — the fundamental, technical and alternative-data breakdown and the recommendation.

Sign up to read the full analysis

What’s Driving HAE’s AI Score?

Fundamentals

Revenue for the last quarter was $339M. This represents a decrease of 2.01% compared to the quarter before it, indicating a need for concern. Compared to the same quarter last year, there is an increase of 5.60%, suggesting positive year-over-year growth. Net income for the last quarter was $33M. This is an increase of -263.85% compared to the quarter before it, which is a positive sign of growth. However, compared to the same quarter last year, there is a decrease of 3.00%, which may be a cause for concern. Ebitda for the last quarter was $75M. This is an increase of 1,639.29% compared to the quarter before it, which is a positive sign of growth. However, compared to the same quarter last year, there is a decrease of 20.29%, which may be a cause for concern. The current P/E ratio is 49.61. This may be considered high, potentially indicating overvaluation and a bearish outlook.

See Haemonetics Corporation’s earnings and insider transactions.

Technicals

Today's stock price is $102.69. This is an increase of 13.09% compared to a month ago, indicating a positive short-term trend. Compared to a year ago, there is an increase of 101.27%, suggesting a positive long-term trend. The trend is bearish. The current SMA10 is $102.70, which is lower than the previous SMA10 of $102.72. This suggests a potential downward trend in price movement. The RSI is 35.9, indicating a neutral condition.

See the full technical analysis and price prediction.

Alternative data

The business outlook among employees at Haemonetics Corporation is low (an estimate of only 31% of employees have a positive outlook), a concerning sign. Add to that that the business outlook is down by -14% in the last couple of months, an even more concerning trend. Haemonetics Corporation has an estimate of 51,000 visitors to their webpage. The number of visitors is up by 31% in the last couple of months, a bullish trend as this can indicate can increase in customers.

Explore Haemonetics Corporation’s job postings, web traffic and app downloads.

Sentiment & social

The sentiment for the stock on various stock forums is high, a positive sign. Haemonetics Corporation has 960 followers on their Twitter page, with no meaningful increase or decrese in the last couple of months.

Track Haemonetics Corporation’s market sentiment.

Frequently Asked Questions: Haemonetics Corporation AI Stock Analysis

Haemonetics Corporation's AltIndex AI Score is 46/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.

AltIndex's AI Score model rates Haemonetics Corporation a Hold (46/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.

The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.

AltIndex generates a complete written AI analysis of Haemonetics Corporation — company overview, fundamentals, technicals and alternative data, with a recommendation. See the HAE AI Score or sign up to read the full thesis.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.